Afinitor Approval Expanded to Include Benign Kidney Tumors

HealthDay – 16 hrs ago FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with a rare genetic condition called tuberous sclerosis complex (TSC), the agency said in a news release.

TSC causes non-cancerous tumors of the brain, kidney and other organs, the FDA said. The disease affects up to 40,000 people in the United States, and as many as 80 percent develop kidney problems.

Afinitor helps suppress these tumors by blocking a protein that's essential for their development and growth, the FDA said.

The drug's safety and effectiveness were clinically evaluated among 118 people with TSC. The most common side effects were inflamed or sore mouth, nausea and vomiting, acne, eczema, cough, headache, diarrhea, abdominal pain, joint pain and swelling of the legs or arms. Some 15 percent of females who took Afinitor missed at least one menstrual period.

Afinitor was first approved by the FDA in 2009 to treat kidney tumors that weren't treated successfully with other drugs.

Afinitor is produced by Novartis, based in East Hanover, N.J.

More information

To learn more about this drug, visit the U.S. National Cancer Institute.

View the Original article

A New Research-Based Sun Safety Program at 40 Hotels and Resorts in the United States to Include Sun Protection Clothing

Share: Tweet02
Apr
2012The Go Sun Smart program is planned for 40 selected resorts in the United States over the next three years and Sun Threadz, a sun protection clothing company, has been invited to be part of this program. Sun Threadz are designed and produced in the USA.

Philadelphia, PA-NJ (1888PressRelease) April 02, 2012 - Go Sun Smart is a research study sponsored by San Diego State University. The purpose of the project is to educate vacationing Americans about comprehensive sun safety techniques and skin cancer prevention. The study is funded by the National Cancer Institute, and has the potential to reach a significant portion of the US population when they are most vulnerable to skin damage from the sun.

Sun Threadz will join the Go Sun Smart project in the fight against skin cancer. Employees of the project will be outfitted in sun safe attire and will visit the resorts and interface with vacationers from a nationwide market. Damage from the sun can be prevented by applying sunscreen, wearing sun protective clothing, wide brim hats, seeking shade when necessary and recognizing when UV is highest and most dangerous.

This program will start the beginning of spring 2012 at twenty resorts and the other twenty resorts will receive the program one year later.

Over one million cases of non-melanoma skin cancers occur annually, and melanoma increased 4% each year for decades, significantly burdening the nation's health system.

The program will use positive, upbeat messages and stories that stress gains from being sun safe consistent with guests' positive vacation experiences to encourage advanced sun safety behaviors. Vacationers will receive important and accessible information that can shift their understanding about over-exposure to the sun while vacationing. Sun safety behaviors are easy to implement but reminders are required to convince vacationers to be sun safe.

Sun Threadz was founded by a melanoma survivor who is an advocate for a sun safe lifestyle.

###  Other Related Press Releases

by Sun Threadz

Texas Stallions Track Club set to host 1st Annual Texas Stallions Relays by Texas Stallions Track Club

Contact Information

Colleen Dougherty Bronstein

Sun Threadz

1390 Knox Drive Yardley, PA

19067

Voice: 215-805-6002

Visit our Site

Press Release Tools

   

View the Original article